Korro Bio appoints Todd Chappell as COO

Korro Bio announced on July 14, 2023, the proposed business combination with Frequency Therapeutics, a publicly listed company, and its concurrent financing of approximately $117M before expenses with leading healthcare specialist investors, which is expected to close immediately prior to completion of the merger. Frequency Therapeutics’ Annual Meeting of Stockholders, at which Frequency’s stockholders will vote on matters related to the business combination, is scheduled for November 3, 2023. Korro Bio expects to close both the financing and merger promptly after the required approvals are obtained from Frequency’s stockholders. In anticipation of the closing of the previously announced merger and as previously disclosed in Frequency’s prospectus related to the merger filed with the Securities and Exchange Commission on September 29, 2023, Korro Bio announced the appointment of Tim Pearson as an independent Board member of the combined company and the Chair of its Audit Committee. This appointment will be effective upon completion of the merger. Mr. Pearson has over 30 years of healthcare experience and has served as CEO of Carrick Therapeutics since July 2019. In addition, and as previously disclosed in the prospectus related to the merger, Korro Bio announced the elevation of Todd Chappell, MBA, to the position of COO Mr. Chappell most recently served as Korro Bio’s Senior Vice President, Strategy and Portfolio Planning.